An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care

Active, not recruitingOBSERVATIONAL
Enrollment

700

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Hormone-sensitive Prostate Cancer
Trial Locations (1)

M6G 1A1

Pentavere, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY